S1456 Real World Outcomes of Upadacitinib Compared to Risankizumab as Second-Line Therapy in Patients With Crohn’s Disease Exposed to Tumor Necrosis Factor-Alpha Inhibitors
Year: 2025
Type: conference-abstract
Authors: Mira Sridharan, Nikita Patel, Gursimran Kochhar, Aakash Desai
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Genetics
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4417163449
Cites:
Cited by:
Related to: